Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Neuromyelitis Optica Spectrum Disease (NMOSD)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableEnded earlyNCT07247292
What this trial is testing

Epidemiological Study of Treatment Approaches on AQP4-IgG Positive NMOSD in Russia

Who this might be right for
Rare DiseasesNeuromyelitis Optica Spectrum Disorder (NMOSD)
AstraZeneca 3
Early research (Phase 1)Looking for participantsNCT07526493
What this trial is testing

Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.

Who this might be right for
Multiple Sclerosis (MS)Neuromyelitis Optica Spectrum Disorder (NMOSD)Autoimmune Encephalitis (AE)+4 more
Tongji Hospital 6
Post-approval studies (Phase 4)Ended earlyNCT05269667
What this trial is testing

A Study In Neuromyelitis Optica Spectrum Disorder (NMOSD) With Satralizumab As An Intervention

Who this might be right for
Neuromyelitis Optica Spectrum DisorderNMOSD
Hoffmann-La Roche 4
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07738952
What this trial is testing

Safety and Efficacy Study of Sivelestat in Neuromyelitis Optica Spectrum Disorder

Who this might be right for
Neuromyelitis Optica Spectrum Disorder Attack
Kyushu University 7
Large-scale testing (Phase 3)Looking for participantsNCT07420296
What this trial is testing

Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder

Who this might be right for
Neuromyelitis Optica Spectrum Disorders (NMOSD)
Tianjin Medical University General Hospital 198
Large-scale testing (Phase 3)Study completedNCT04201262
What this trial is testing

An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD

Who this might be right for
Neuromyelitis OpticaNeuromyelitis Optica Spectrum Disorder
Alexion Pharmaceuticals, Inc. 58
Not applicableLooking for participantsNCT07762872
What this trial is testing

Prospective Real-World Effectiveness and Safety of Satralizumab in the Early Treatment of Attacks in NMOSD

Who this might be right for
Neuromyelitis Optica Spectrum Disorders (NMOSD)
Junwei Hao, MD 50
Post-approval studies (Phase 4)UnknownNCT06212245
What this trial is testing

A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders

Who this might be right for
Neuromyelitis Optica Spectrum Disorders
Hansoh BioMedical R&D Company 33
Early research (Phase 1)WithdrawnNCT03605238
What this trial is testing

Treatment of Relapsed and/or Refractory AQP4-IgG Seropositive NMOSD by Tandem CAR T Cells Targeting CD19 and CD20

Who this might be right for
Neuromyelitis Optica Spectrum Disorder
Chinese PLA General Hospital
Not applicableLooking for participantsNCT05966467
What this trial is testing

Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies

Who this might be right for
Neuromyelitis Optica Spectrum DisorderNMOSDAQP4+ NMOSD
Alexion Pharmaceuticals, Inc. 122
Large-scale testing (Phase 3)Ended earlyNCT01892345
What this trial is testing

Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)

Who this might be right for
Neuromyelitis OpticaNeuromyelitis Optica Spectrum Disorder
Alexion Pharmaceuticals, Inc. 143
Post-approval studies (Phase 4)Looking for participantsNCT07410039
What this trial is testing

Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study

Who this might be right for
Neuromyelitis Optica Spectrum Disorder Attack
Chinese PLA General Hospital 200
Large-scale testing (Phase 3)Looking for participantsNCT07557420
What this trial is testing

Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)

Who this might be right for
NMOSDNeuromyelitis Optica Spectrum Disorder
Alexion Pharmaceuticals, Inc. 19
Post-approval studies (Phase 4)Study completedNCT05896605
What this trial is testing

Monitoring of Azathioprine Metabolite Concentrations and Cytokine Levels in Neuromyelitis Optica Spectrum Disorder

Who this might be right for
NMO Spectrum DisorderAzathioprine Adverse Reaction
First Affiliated Hospital of Guangxi Medical University 63
Not applicableEnrolling By InvitationNCT06374264
What this trial is testing

Acceptability and Safety of MR-C-014 in Persons With Neuromyelitis Optica Spectrum Disorder

Who this might be right for
Neuromyelitis Optica Spectrum Disorder
MedRhythms, Inc. 30
Large-scale testing (Phase 3)WithdrawnNCT03829566
What this trial is testing

Autologous Transplant To End NMO Spectrum Disorder

Who this might be right for
Neuromyelitis OpticaDevic's DiseaseNMO Spectrum Disorder
Northwestern University
Not applicableEnded earlyNCT04131764
What this trial is testing

Diagnosis of ON With or Without MS or NMOSD

Who this might be right for
Multiple SclerosisNeuromyelitis Optica Spectrum Disorder AttackNeuromyelitis Optica Spectrum Disorder Relapse+2 more
Jagannadha R Avasarala 112
Early research (Phase 1)Looking for participantsNCT06249438
What this trial is testing

C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy

Who this might be right for
Systemic Lupus Erythematosus (SLE)Immune-mediated Necrotizing Myopathy (IMNM)Neuromyelitis Optica Spectrum Disorders (NMOSD)+3 more
RenJi Hospital 30
Not applicableStudy completedNCT05840055
What this trial is testing

ACT with NMOSD Patients and Caregivers Pilot Study

Who this might be right for
NMO Spectrum Disorder
Thomas Jefferson University 43
Large-scale testing (Phase 3)Study completedNCT02028884
What this trial is testing

Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)

Who this might be right for
Neuromyelitis Optica (NMO)NMO Spectrum Disorder (NMOSD)
Hoffmann-La Roche 85
Next Page